Ganirelix Acetate, marketed by Amphastar Pharmaceuticals, is used in assisted reproductive technology (ART) to prevent premature ovulation in women undergoing controlled ovarian stimulation [1].
Why is Ganirelix used in IVF?
Ganirelix Acetate is a gonadotropin-releasing hormone (GnRH) antagonist. It works by suppressing the surge of luteinizing hormone (LH) that can trigger premature ovulation. This suppression helps ensure that eggs mature fully before they are retrieved for in vitro fertilization (IVF) procedures [2].
How does Ganirelix work to prevent ovulation?
By binding to GnRH receptors in the pituitary gland, Ganirelix Acetate directly blocks the release of LH and follicle-stimulating hormone (FSH). This immediate blockade prevents the LH surge, which is critical for ovulation [3].
What is the difference between Ganirelix and Lupron?
Ganirelix (a GnRH antagonist) provides a more immediate suppression of LH compared to Lupron (a GnRH agonist). Lupron initially stimulates LH and FSH release before downregulating the receptors, a process that takes longer [4]. This difference means Ganirelix typically requires a shorter treatment duration and may be associated with fewer side effects like ovarian hyperstimulation syndrome (OHSS) in some protocols [5].
When does Ganirelix patent protection expire?
Information on specific patent expiry dates for Ganirelix, including for Amphastar's version, can be found on DrugPatentWatch.com [6]. Patent landscapes for established drugs are complex and can involve multiple patents covering different aspects of the drug and its manufacturing.
Who manufactures Ganirelix?
Amphastar Pharmaceuticals is one of the manufacturers of Ganirelix Acetate. Other companies also produce generic versions of ganirelix [1].
What are the common side effects of Ganirelix?
Common side effects reported with Ganirelix Acetate include headache, nausea, and reactions at the injection site such as redness, itching, or swelling [1][2].
Can biosimilars enter the market before patent expiry?
For small molecule drugs like Ganirelix, the concept of "biosimilars" does not directly apply. Instead, generic versions can be approved and enter the market once patents expire or are successfully challenged, provided they demonstrate bioequivalence [7].
What are the clinical outcomes associated with Ganirelix use?
Studies and clinical trials have demonstrated the efficacy of GnRH antagonists like Ganirelix in achieving successful egg retrieval and pregnancy rates in ART cycles when used in appropriate protocols [3][5].
Sources:
[1] https://www.amphastar.com/products/ganirelix-acetate-injection/
[2] https://www.rxlist.com/ganirelix-drug.htm
[3] https://www.ncbi.nlm.nih.gov/books/NBK279557/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703418/
[5] https://www.fertstert.org/article/S0015-0282(10)61672-8/fulltext
[6] https://drugpatentwatch.com/
[7] https://www.fda.gov/drugs/generic-drugs/what-biosimilar-and-interchangeable-biosimilar